GTR, compared to STR, was significantly associated with prolonged PFS in patients with low-grade glioma [22], and isocitrate dehydrogenase-wild-type GBM [26]; reduced progression at 2, 5, and 10 years in low-grade glioma patients [23]; decreased 6-month progression in infratentorial pediatric high-grade gliomas [24]; reduced 1-year progression in GBM patients [39]; and improved 1-, 3-, and 5-year PFS in glioma patients [25]. This evidence concerns the gene IDH3A and glioblastoma.